source
- Novartis drops mid-stage radioligand therapy 177Lu-NeoB after weak early dataNovartis has discontinued its mid-stage radioligand therapy 177Lu-NeoB, which was being tested for breast cancer and other solid tumors. The company said early clinical data did not show enough ef…
- MDCG: Only manufacturers should assign UDI-DIsThe European Commission's Medical Device Coordination Group (MDCG) says unique device identifiers and device identifiers (UDI-DI) codes used between manufacturers and distributors need to be better…